@article{782b6d414975487aa406a4993cd0e9a0,
title = "Idelalisib immune-related toxicity is associated with improved treatment response",
abstract = "Idelalisib is associated with increased occurrence of immune-related adverse events (irAEs). Clinical observations suggest a correlation between immune checkpoint inhibitor–induced irAEs and survival outcomes in patients with solid tumors; however, this relationship in hematologic malignancies is not well understood. In a post hoc analysis of 3 registrational trials, we explored the relationship between Grade ≥3 diarrhea/colitis and alanine/aspartate transaminase (ALT/AST) elevation incidences and efficacy endpoints in patients with indolent non-Hodgkin lymphoma (iNHL), follicular lymphoma (FL), and chronic lymphocytic leukemia treated with idelalisib. Grade ≥3 diarrhea/colitis was associated with higher overall response rate (ORR) and longer progression-free survival (PFS) for all subgroups. Grade ≥3 ALT/AST elevations were associated with improved duration of response and overall survival for all subgroups and improved ORR and PFS for patients with FL or iNHL. Our analysis in hematologic malignancies showed a trend correlating idelalisib-induced Grade ≥3 irAEs with improved efficacy.",
keywords = "Idelalisib, PI3K inhibitor, chronic lymphocytic leukemia, follicular lymphoma, immune-related adverse event, indolent non-Hodgkin lymphoma",
author = "Wagner-Johnston, {Nina D.} and Jeff Sharman and Furman, {Richard R.} and Gilles Salles and Brown, {Jennifer R.} and Tadeusz Robak and Lin Gu and Guan Xing and Chan, {Rebecca J.} and Nishanthan Rajakumaraswamy and Gopal, {Ajay K.}",
note = "Funding Information: J.R.B. has served as a consultant for AbbVie; Acerta; Astra-Zeneca; Beigene; Catapult; Dynamo Therapeutics; Eli Lilly; Genentech/Roche; Gilead Sciences, Inc; Janssen; Juno/Celgene/Bristol-Myers Squibb; Kite, a Gilead company; Loxo; MEI Pharma; MorphoSys AG; Nextcea; Novartis; Octapharma; Pfizer; Pharmacyclics; Redex; Rigel; Sun Pharmaceutical Industries, Inc.; Sunesis; TG Therapeutics; and Verastem; received research funding from Gilead Sciences, Inc.; Loxo/Lilly; Sun Pharmaceutical Industries, Inc.; TG Therapeutics; and Verastem/SecuraBio; received honoraria from Janssen and Teva; and served on data safety monitoring committees for Invectys and MorphoSys. Funding Information: A.K.G. reports grants and nonfinancial research support from Bristol-Myers Squibb, Effector, Janssen, Merck, Pfizer, Seattle Genetics, Takeda, and Teva; consulting fees, personal fees and nonfinancial support from Acerta; Amgen; Aptevo; Asana Bio; BRIM bio; Compliment; Gilead Sciences, Inc.; I-Mab Biopharma; Incyte; Janssen; Pfizer; Sanofi; Seattle Genetics; and Spectrum. Publisher Copyright: {\textcopyright} 2021 Informa UK Limited, trading as Taylor & Francis Group.",
year = "2021",
doi = "10.1080/10428194.2021.1948038",
language = "English (US)",
volume = "62",
pages = "2915--2920",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",
}